Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Rhamnolipids, Microbial Virulence Factors, in Alzheimer's Disease.

Andreadou E, Pantazaki AA, Daniilidou M, Tsolaki M.

J Alzheimers Dis. 2017;59(1):209-222. doi: 10.3233/JAD-161020.

PMID:
28598837
2.

Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.

Portelius E, Zetterberg H, Skillbäck T, Törnqvist U, Andreasson U, Trojanowski JQ, Weiner MW, Shaw LM, Mattsson N, Blennow K; Alzheimer’s Disease Neuroimaging Initiative.

Brain. 2015 Nov;138(Pt 11):3373-85. doi: 10.1093/brain/awv267. Epub 2015 Sep 15.

3.

A new assay for rhamnolipid detection-important virulence factors of Pseudomonas aeruginosa.

Laabei M, Jamieson WD, Lewis SE, Diggle SP, Jenkins AT.

Appl Microbiol Biotechnol. 2014 Aug;98(16):7199-209. doi: 10.1007/s00253-014-5904-3. Epub 2014 Jun 29.

PMID:
24974281
4.

Synaptic change in the posterior cingulate gyrus in the progression of Alzheimer's disease.

Scheff SW, Price DA, Ansari MA, Roberts KN, Schmitt FA, Ikonomovic MD, Mufson EJ.

J Alzheimers Dis. 2015;43(3):1073-90. doi: 10.3233/JAD-141518.

5.

Interactions between amyloid-β and tau in cerebrospinal fluid of people with mild cognitive impairment and Alzheimer's disease.

Kristofikova Z, Ricny J, Kolarova M, Vyhnalek M, Hort J, Laczo J, Sirova J, Ripova D.

J Alzheimers Dis. 2014;42 Suppl 3:S91-8. doi: 10.3233/JAD-132393.

PMID:
24670397
6.

Serum antibodies to periodontal pathogens are a risk factor for Alzheimer's disease.

Sparks Stein P, Steffen MJ, Smith C, Jicha G, Ebersole JL, Abner E, Dawson D 3rd.

Alzheimers Dement. 2012 May;8(3):196-203. doi: 10.1016/j.jalz.2011.04.006.

7.

Decreased levels of guanosine 3', 5'-monophosphate (cGMP) in cerebrospinal fluid (CSF) are associated with cognitive decline and amyloid pathology in Alzheimer's disease.

Ugarte A, Gil-Bea F, García-Barroso C, Cedazo-Minguez Á, Ramírez MJ, Franco R, García-Osta A, Oyarzabal J, Cuadrado-Tejedor M.

Neuropathol Appl Neurobiol. 2015 Jun;41(4):471-82. doi: 10.1111/nan.12203.

PMID:
25488891
8.

Brain glutamate levels are decreased in Alzheimer's disease: a magnetic resonance spectroscopy study.

Fayed N, Modrego PJ, Rojas-Salinas G, Aguilar K.

Am J Alzheimers Dis Other Demen. 2011 Sep;26(6):450-6. doi: 10.1177/1533317511421780. Epub 2011 Sep 15.

PMID:
21921084
9.

High avidity HSV-1 antibodies correlate with absence of amnestic Mild Cognitive Impairment conversion to Alzheimer's disease.

Agostini S, Mancuso R, Baglio F, Cabinio M, Hernis A, Costa AS, Calabrese E, Nemni R, Clerici M.

Brain Behav Immun. 2016 Nov;58:254-260. doi: 10.1016/j.bbi.2016.07.153. Epub 2016 Jul 25.

PMID:
27470229
10.

The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer's Disease.

De Vos A, Struyfs H, Jacobs D, Fransen E, Klewansky T, De Roeck E, Robberecht C, Van Broeckhoven C, Duyckaerts C, Engelborghs S, Vanmechelen E.

J Alzheimers Dis. 2016 Jul 6;53(4):1523-38. doi: 10.3233/JAD-160227.

11.

Human cerebrospinal fluid fatty acid levels differ between supernatant fluid and brain-derived nanoparticle fractions, and are altered in Alzheimer's disease.

Fonteh AN, Cipolla M, Chiang J, Arakaki X, Harrington MG.

PLoS One. 2014 Jun 23;9(6):e100519. doi: 10.1371/journal.pone.0100519. eCollection 2014.

12.

White matter signal abnormality quality differentiates mild cognitive impairment that converts to Alzheimer's disease from nonconverters.

Lindemer ER, Salat DH, Smith EE, Nguyen K, Fischl B, Greve DN; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2015 Sep;36(9):2447-57. doi: 10.1016/j.neurobiolaging.2015.05.011. Epub 2015 May 28.

13.

Proton magnetic resonance spectroscopy in mild cognitive impairment and Alzheimer's disease: a preliminary study.

Suriyajakryuththana W, Tuntiyatorn L, Teepprasarn N, Sukying C.

J Med Assoc Thai. 2014 Apr;97(4):407-14.

PMID:
24964683
14.

Elevated Galectin-3 Levels in the Serum of Patients With Alzheimer's Disease.

Wang X, Zhang S, Lin F, Chu W, Yue S.

Am J Alzheimers Dis Other Demen. 2015 Dec;30(8):729-32. doi: 10.1177/1533317513495107. Epub 2013 Jul 2.

PMID:
23823143
15.

Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer's disease and in mild cognitive impairment due to AD.

Sanfilippo C, Forlenza O, Zetterberg H, Blennow K.

J Neural Transm (Vienna). 2016 Dec;123(12):1443-1447. Epub 2016 Aug 16.

PMID:
27531278
16.

Autoantibodies Toward the Angiotensin 2 Type 1 Receptor: A Novel Autoantibody in Alzheimer's Disease.

Giil LM, Kristoffersen EK, Vedeler CA, Aarsland D, Nordrehaug JE, Winblad B, Cedazo-Minguez A, Lund A, Reksten TR.

J Alzheimers Dis. 2015;47(2):523-9. doi: 10.3233/JAD-150053.

PMID:
26401573
17.

Integrating Biomarkers for Underlying Alzheimer's Disease in Mild Cognitive Impairment in Daily Practice: Comparison of a Clinical Decision Support System with Individual Biomarkers.

Rhodius-Meester HF, Koikkalainen J, Mattila J, Teunissen CE, Barkhof F, Lemstra AW, Scheltens P, Lötjönen J, van der Flier WM.

J Alzheimers Dis. 2016;50(1):261-70. doi: 10.3233/JAD-150548.

PMID:
26577521
18.

Increased cerebrospinal fluid levels of double-stranded RNA-dependant protein kinase in Alzheimer's disease.

Mouton-Liger F, Paquet C, Dumurgier J, Lapalus P, Gray F, Laplanche JL, Hugon J; Groupe d'Investigation du Liquide Céphalorachidien Study Network.

Biol Psychiatry. 2012 May 1;71(9):829-35. doi: 10.1016/j.biopsych.2011.11.031. Epub 2012 Jan 26.

PMID:
22281122
19.

Pro-inflammatory S100A9 Protein as a Robust Biomarker Differentiating Early Stages of Cognitive Impairment in Alzheimer's Disease.

Horvath I, Jia X, Johansson P, Wang C, Moskalenko R, Steinau A, Forsgren L, Wågberg T, Svensson J, Zetterberg H, Morozova-Roche LA.

ACS Chem Neurosci. 2016 Jan 20;7(1):34-9. doi: 10.1021/acschemneuro.5b00265. Epub 2015 Nov 12.

PMID:
26550994
20.

Association between white matter hyperintensity and medial temporal atrophy at various stages of Alzheimer's disease.

Kandiah N, Chander RJ, Ng A, Wen MC, Cenina AR, Assam PN.

Eur J Neurol. 2015 Jan;22(1):150-5. doi: 10.1111/ene.12546. Epub 2014 Aug 21.

PMID:
25142829

Supplemental Content

Support Center